The annual J.P. Morgan Conference is a key event in the healthcare sector, bringing together industry leaders, startups, and investors to explore the latest innovations and trends shaping the industry. This year’s conference, held in San Francisco, saw a wave of optimism as the industry looks to build on the momentum of the previous year.
In 2025, the healthcare industry faced geopolitical uncertainty and slower dealmaking in the first half of the year. However, the pace picked up in the second half, with several deals over $10 billion. The industry is now poised to continue this momentum, with a strong innovation landscape driving large pharmas like Bayer to seek out new partnerships and acquisitions. Additionally, positive capital markets and potentially lower interest rates are creating a favorable environment for investments.
One of the key trends to watch this year is the surge in dealmaking and M&A activity. Large pharmas are on the lookout for best-in-class and first-in-class opportunities to further develop and commercialize. The industry is experiencing a renaissance moment, driven by advances in science and emerging modalities that were not on the horizon a decade ago.
China’s influence in the biotech industry is also on the rise. The country has transitioned from developing “me too” drugs to delivering truly novel assets across multiple therapeutic areas. With a favorable policy environment and cost-effective clinical trials, China has become a major player in the global biotech landscape.
AI continues to play a crucial role in drug discovery, with companies like NVIDIA and Eli Lilly investing in co-innovation labs to tackle the toughest challenges in drug development. While AI has shown promise in identifying novel targets and streamlining clinical trials, the industry is still waiting for a drug discovered solely by AI to hit the market.
Global market dynamics, particularly around drug pricing, present challenges for pharma and biotech companies. The issue of pricing disparities between the U.S. and other developed nations has led to complex negotiations and policy changes. The emergence of new therapeutic modalities, such as siRNA and xenotransplantation, offers hope for significant advancements in patient care across various diseases.
As the industry continues to evolve, there is great potential for emerging medicines to transform the lives of millions of patients. Stay tuned for further updates on the exciting opportunities and developments shaping the healthcare landscape this year. Thank you to Kira Peikoff for her contributions to this article.
